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The evolution of biologics in the context 
of oncological therapy 
ABSTRACT
Progress in the field of pharmacy, closely related with the mutual stimulation of natural sciences and new technolo-
gies available to researchers, has been so rapid over the last few decades that it has begun to cause problems at 
the level of definitions and classifications. This phenomenon refers also to the term of biologics or, more widely, 
to biopharmaceuticals (in Polish terminology). The first associations with the above terms lead our thoughts to 
recombinant proteins, such as insulin used in the treatment of diabetes or monoclonal antibodies with wide, in 
terms of therapeutic areas, applications. It is generally believed that the above category of drugs is not associated 
with preparations invented long before the discovery of nucleic acids, let alone before the invention of an ordinary 
bulb. Importantly, the connotation of the term biopharmaceuticals is undergoing a very rapid reconstruction before 
our eyes, and the set of referents is expanding with newer, previously unknown types of therapies. Technological 
progress is one of the driving forces of these changes. Unmet medical needs, including the ones in the area of 
oncology, constitute another driving force. 
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A brief history of biopharmaceuticals
In the broadest sense, the history of biopharma-
ceuticals, although uncaptured and unclassified as part 
of meta-science for many years, begins as early as the 
second half of the 18th century. Its beginning is synony-
mous with the bold achievements of Edward Jenner, 
an English physician, who believed in underestimated 
folk wisdom, according to which the history of cowpox 
(a contagious viral disease of domestic cattle and pigs) 
gave immunity to smallpox. Thus, Jenner used material 
from people infected with animal smallpox to develop 
the first effective vaccine against deadly smallpox [1]. 
As a matter of fact, there are reports indicating that the 
first vaccination was made by a farmer named Jesty, 
22 years before Jenner himself. However, it was Jenner 
who is, due to his striving for the spread of his discovery 
and his approach based on a scientific method, widely 
recognised as the inventor and precursor of the applica-
tion of products of biological origin [2].
Another great breakthrough occurred in the 1940s 
when the development of technology was driven by 
the world-engaging war. The needs of the front and 
the necessity to gain an advantage on it involved huge 
investments in research based on the observations of 
Alexander Fleming. Although he discovered bacteri-
cidal mould as early as in 1928, the interest in his work 
first by Ernst Chain and Howard Florey, and later also 
by Norman Heatley, an English biochemist, came in 
the late 1930s [3]. After presenting the research re-
sults of the team of these scientists at the University of 
Oxford, American pharmaceutical companies became 
interested in penicillin. However, after internal evalu-
ation, none of these companies continued studying the 
issue. It is only the interest from the American War 
Production Board that changed the course of history. 
Contracts for mutual exchange of information between 
Merck, Squibb, Pfizer, Midwest, Abbott Laboratories, 
Upjohn, Parke, and Davis were signed. The method of 
production in milk cans was replaced by a large-scale 
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manufacturing process based on a highly effective 
fungal strain selected during the development. By the 
end of 1944, penicillin demonstrated its usefulness in 
military use, and in March 1945 it entered the domestic 
and foreign markets [4].
The beginning of the rapid development of biologi-
cal therapies is, however, associated with a completely 
different therapeutic area than infectious diseases. It 
refers to the application of insulin in the therapy of 
diabetes. Scientific intuition led researchers to discover 
insulin from the second half of the 19th century, when 
Paul Langerhans characterised a group of pancreatic 
cells of distinct structure as compared to the remaining 
ones. This group was later named the islets of Langer-
hans, in honour of its discoverer, by Gustaw Laguesse, 
a French pathologist [5]. Edward Albert Sharpey-Schäfe, 
an English physiologist, observed afterwards that they 
produced a substance capable of lowering blood sugar 
levels. Consequently, in line with the emerging termi-
nology, he used the name applied in 1909 by Jean de 
Meyer and introduced the term of insulin to medicine 
(Latin: Insula — island). The newly discovered molecule 
began to gain medical and commercial significance 
only as a result of the work of scientists from Toronto: 
Frederick Banting, Charles Best, and James Collip. 
They developed a method of insulin extraction from the 
pancreas of animals based on optimised alcohol concen-
tration. Even before clinical trials were completed, Eli 
Lilly’s production facilities started to manufacture the 
protein, and then to introduce the innovative therapy 
to the pharmaceutical market in 1922 and revolutionise 
the approach to diabetes treatment. In the subsequent 
decades, it was possible to sequence and synthesise in-
sulin, which, combined with the discoveries attributed to 
Watson and Crick, caused another revolution at the end 
of the 1970s. In 1978, the company Genentech, originat-
ing in California, a pioneer in the field of pharmaceutical 
biotechnology, in cooperation with the City of Hope 
National Medical Centre, developed the first insulin 
using recombinant DNA technology. Thanks to this, as 
early as in 1982, the above-mentioned Eli Lilly, as a li-
censee, implemented the first recombinant drug called 
Humulin, produced in a bacterial expression system, 
opening a new era in the development of pharmacy [6].
The era of DNA recombination 
Almost immediately after insulin, recombinant 
human growth hormone (Protropin; 1985) and inter-
feron-alpha variants (Roferon A, Intron A; 1986) were 
introduced. Production of recombinant vaccines was 
started as well (Recombivax; 1985). The 1980s and 
1990s were the times of the so-called first-generation 
biopharmaceuticals — recombinant proteins identi-
cal in structure to native human proteins, mainly 
hormones, cytokines, enzymes, growth factors, and 
blood coagulation factors. In the second half of the 
1990s, excluding several previous cases, the so-called 
second-generation biopharmaceuticals entered the 
market, i.e. molecules with a modified sequence, ex-
changed sugar residues, surface modified molecules 
through a covalent bond with polyethylene glycol, and 
so-called fusion proteins, being the combination of two 
or more sequences. The objective of the above vari-
ations was to improve efficiency, reduce the number 
of side effects, and achieve better pharmacokinetic 
parameters. Exemplary molecules are fast-acting (Hu-
malog; 1996) and long-acting (Lantus; 2000) types of 
insulin, and pegylated interferons alpha (Peg-Intron; 
2000 and Pegasys; 2002). The instances of even more 
technologically complex solutions include etanercept, 
i.e. the fusion of the crystallisable fragment (Fc) of 
the IgG1 antibody (immunoglobulin) with fragments 
of the tumour necrosis factor (TNF) receptor (Enbrel; 
1998) and the fusion of diphtheria toxin with interleu-
kin-2 (IL-2) (Ontak; 1999) [7].
Initially, prokaryotic expression systems based 
mainly on E. coli strains were used to produce bio-
pharmaceuticals based on recombinant DNA tech-
nologies. They enabled, in a relatively inexpensive way, 
the acquisition of so-called high-density cell cultures, 
from which, after disintegration of bacterial cells, most 
often using chromatographic techniques, the target 
therapeutic proteins were purified. Although the 
E. coli system has been successfully applied to pro-
duce numerous molecules to this day, over the years, 
with the increase in complexity of the drug structure 
(molecular weight, post-translational modifications, 
complex fusions) and attempts to eliminate the prob-
lem of immunogenicity, more demanding methods in 
the form of the eukaryotic expression systems have 
started to be used. These were strains of S. cerevisiae 
(e.g. lutropin — Luveris), BHK cell lines, i.e. Baby 
Hamster Kidney (e.g. blood coagulation factor VIII 
— Kogenate), and, above all, CHO cell lines, i.e. Chi-
nese Hamster Ovary, which is of utmost significance 
for development of antibody production methods 
(few examples of mAbs molecules are based on the 
hybridoma system). 
Thus, progress in molecular biology and biotech-
nology generated over 200 biologics by 2015. Their 
sales reached an incredible value of 196 billion USD 
in 2015, which accounted for 29% of the market for 
all drugs. This value exceeded the estimates of market 
analysts — in the report ‘Global Protein Therapeutics 
Market Forecast to 2015’ published in 2012 by RNCOS, 
it was estimated that the biopharmaceuticals market 
would reach 143 billion USD in 2015 [8]. Kelly Scientific 
Research estimates from 2015 point to further increases 
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— the value of the biological drug market is expected 
to reach 463 billion USD in 2021, accounting for 32% 
of the entire drug market (Fig. 1) [9]. Importantly, at 
the end of 2015, over 900 new biopharmaceuticals in 
the form of protein molecules and antibodies, cellular 
therapies, as well as gene and antisense therapies were 
under development. Over 5000 subsequent projects 
were subject to early laboratory evaluations at that 
time. It cannot be disputed that the discussed field is 
still developing very rapidly. However, biologics have 
already found their application in many therapeutic 
areas and individual indications, including the following: 
diabetes, neutropaenia, thrombocytopaenia, anaemia, 
hepatitis, growth deficiency, myocardial infarction and 
heart failure, strokes, and a number of autoimmune 
diseases. Their application in cancer treatment is also 
growing (Fig. 2). 
Figure 1. Value of the market of biologics in particular regions (based on [9])
Definition of biopharmaceuticals 
as well as benefits and problems 
associated with their use
According to the FDA, biopharmaceuticals (biolo-
gics, biopharmaceuticals, biological medical products) 
are products generated by and isolated from living or-
ganisms. They can be of natural origin (human, animal, 
or microorganism) or produced with the application 
of biotechnological methods. They include the follow-
ing: vaccines, blood components, tissues, cells, gene 
therapies, and therapeutic proteins (including anti-
bodies). They can have a structure based on proteins 
and peptides, sugars, nucleic acids, or their complexes 
or combinations. They can also be living structures, 
such as tissues and cells. Due to the development of 
the technology of producing recombinant molecules 






























Figure 2. Structure of the market of biologics by therapeutic areas (based on [10])  
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to therapeutic recombinant proteins and monoclonal 
antibodies. From the point of view of both the system 
and the physician, as well as the patient, these solutions 
are not free from defects. The complicated manufactur-
ing process affects both the cost of drug development 
and the treatment itself. According to data provided by 
Kelly Scientific Research, in 2015 the average cost of the 
treatment of a patient with biologics was 20–55 times 
higher than the cost of treatment based on so-called 
conventional therapy (small chemical molecules) [9]. 
In addition, biopharmaceuticals, due to lower stability 
than conventional medicines, usually require compliance 
with more stringent storage procedures and preparation 
for administration to the patient. Hospitalisation and 
observation are more frequently required. However, 
their market success is not unfounded. In many cases, 
as a rule, when the molecular target of the drug is 
a structure that does not require penetration through 
the cell membrane (most often the surface receptor or 
its soluble ligand), biologics are the best tool to achieve 
this goal by eliminating the non-specific interactions that 
can cause a whole range of adverse effects. These are, 
by definition, targeted drugs. What is more, due to their 
natural structure, despite a longer, usually favourable 
half-life period associated with molecular weight, they 
are degraded and eliminated from the body without 
the risk of accumulation and long-term deposition in 
the body’s tissues. Also, they do not penetrate the nor-
mal blood-brain barrier. However, the latest scientific 
knowledge and technology that allows the manipulation 
of sugar residues in the production process, enable the 
development of the molecules burdened with the prob-
lem of immunogenicity to a significantly lesser extent. 
Cytokines and immunotoxins
The first biopharmaceuticals used in oncology were 
the above-mentioned recombinant variants of alpha 
interferons. Roferon A and Intron A have been applied 
in the treatment of specific leukaemias, lymphomas, 
sarcomas, melanomas, and kidney tumours. By the end 
of the 1990s, interferons and erythropoietins consti-
tuted the largest share of the recombinant drug market. 
However, over the years, as existing therapies were 
improved and new therapies were introduced, particu-
larly in well-developed countries, it was not possible to 
maintain this dominance. As interferons are a group of 
proteins from the cytokine family involved in numerous 
processes related to the activation of elements of the 
immune system, their application is associated with an 
average number of side effects that are very burdensome 
for the patient. Thus, despite high dynamics of the entire 
market and the fact that the market value of interfer-
ons alone increased (from 5.7 billion USD in 2002 to 
8.6 billion USD in 2009), their total share in the market 
of biologics is systematically falling. In 2002, it was over 
17% [11], in 2009 only 7% [8], and in 2015 less than 5% 
[10]. These calculations should also take into account 
the fact that they apply to all interferons (including beta 
and gamma) and the fact that more than half of the 
sales of alpha interferons is associated with treatment 
of viral infections (mainly hepatitis and AIDS). In terms 
of these indications, subsequent generations of alpha 
interferons, such as Peg-Intron and Pegasys (pegylated 
forms of alpha interferons) were developed.
Another example of cytokines in oncological 
therapy, developed in the 1990s and approved for the 
first time in 1992, is interleukin-2. A molecule called 
aldesleukin has found application in the treatment of 
metastatic kidney cancer and melanoma [12]. Recombi-
nant IL-2 also became part of the structure of a product 
called Ontak (Denileukin Diftitox) constituting the 
recombinant fusion of a cytokine with the diphtheria 
toxin-related  domain approved by the FDA in 1999 in 
the treatment of primary cutaneous lymphomas [13]. 
The same product was withdrawn by the FDA in 2014.
In the context of attempts to implement the concept 
as closely as possible to the ideal of targeted therapy, on 
the wave of achievements in the area of so-called small 
molecules and development of Gleevec, subsequent 
research projects were less frequently directed towards 
non-specific immunotherapy. From the perspective of 
today’s researchers, this approach was relatively brutal. 
The subsequent programs required both completely dif-
ferent molecular goals and ways of their accomplishment. 
Cluster of differentiation 
Rituximab was the first representative of the new 
direction. As part of the mechanism of action of this 
molecule, the idea of targeting is implemented by us-
ing a cluster of differentiation antigens and hits the 
CD20 present on B lymphocytes. Hence, next to au-
toimmune diseases, the huge potential of rituximab is 
noticed in the treatment of non-Hodgkin’s lymphoma 
and lymphocytic leukaemia. What is very important is 
that structurally this molecule is a monoclonal antibody 
capable of inducing antibody-dependent cell cytotoxic-
ity (ADCC), due to the presence of the crystallisable 
fragment (Fc domain) [14]. According to IgeaHub 
estimates for 2018, the total annual sales value of rituxi-
mab (Rituxan and Mabther) was to be about 8.1 billion 
USD. In 2017, under the name of Biogen and Genen-
tech, Rituxan Hycela with recombinant hyaluronidase 
enabling rapid subcutaneous administration, reached 
the market.
At the same time as the first rituximab was under 
development, cluster of differentiation met with inter-
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est from other groups active in the drug discovery field. 
CD52 was applied as a molecular target for the drug 
Campath (alemtuzumab) used to treat B-CLL (B-cell 
chronic lymphocytic leukaemia). It was launched on 
the market in 2001 [15]. The next examples, however, 
represent an even higher level of structural engineering. 
Catumaxomab (Removab), in addition to the CD3 an-
tigen present on T-lymphocytes, binds the EpCAM 
(epithelial cell adhesion molecule) protein — a mo-
lecular target present on the cell surface of many types 
of neoplasms. Catumaxomab is a trifunctional antibody 
for which each of the antigen binding fragments (Fab) 
have an affinity for a different molecular target [16]. 
Blinatumomab (Blincyto) constitutes an even more 
unusual construction. This molecule is a representative 
of Bi-specific T-cell engagers (BiTE) antibodies and 
consists of two single-chain variable fragments (scFv) of 
antibodies linked by a peptide linker. This molecule does 
not have a crystallisable fragment (Fc) of the antibody. 
One of the variable fragments is responsible for binding 
of the CD19 antigen that is subject to expression on the 
surface of B lymphocytes in acute lymphoblastic leukae-
mia, and the other for recruitment of T-lymphocytes by 
direct interaction with the CD3 antigen [17]. An inter-
esting example of attempts to increase the potential of 
antibodies targeting cell differentiation antigens is the 
product Adcetris (brentuximab vedotin) manufactured 
by Seattle Genetics. This drug belongs to the group of 
ADCs (antibody drug conjugates). It is a monoclonal 
antibody directed against CD30 (an antigen present on 
Hodgkin lymphoma cells, cutaneous T-cell lymphoma, 
and anaplastic lymphoma) conjugated by maleimide 
with monomethylated auristatin E [18].
Growth factors
Almost in parallel with the concept of molecules 
targeting clusters of differentiation, attention was paid to 
the possibility of using monoclonal antibody technology 
against a completely different group of molecular targets, 
elements of the growth factor signalling pathways avail-
able outside the cell receptors or their ligands. As signal 
transmitters, these pathways constitute an important 
stimulus in the emergence and progression of numer-
ous neoplastic diseases. The flagship example of a drug 
developed in accordance with this concept is Herceptin 
(trastuzumab) used for 20 years for breast cancer with 
expression of the gene encoding HER2 (human epider-
mal growth factor receptor 2). It is a murine humanised 
antibody directed against HER2 — one of the receptors 
of the EGFR family (epidermal growth factor receptor). 
In 2013, a bioconjugate that was structurally based on 
Herceptin, in which the crystallisable fragment (Fc) of 
the same antibody was combined with thiol groups with 
a small molecule inhibitor of the mitotic cell division, 
mertansine, was launched on the market. The new ADC 
is available under the trade name Kadcyla. The activity 
of the next molecule, which can be used in combination 
with trastuzumab in breast cancer, is directed to the same 
HER2 receptor, but to a different epitope. Pertuzumab 
(Perjeta), first introduced in 2013, blocks a fragment 
of the HER2 receptor responsible for interaction and 
dimerisation with HER3, therefore  preventing the for-
mation of the most active form of the complex capable of 
transmitting the pro-survival signal [19]. Other instances 
of exploration of the EGF family of ligand pathways are 
cetuximab (Erbitux) and panitumumab (Vectibix). Both 
molecules are anti-EGFR monoclonal antibodies. The 
first is a chimeric molecule; the other one is fully human. 
They are applied in metastatic colorectal cancer with 
overproduction of EGFR and KRAS wild type. 
An example of implementation of the slightly differ-
ent strategy for monoclonal antibodies is bevacizumab 
(Avastin) developed by a team from Napoleon Ferrara. 
For many years, it was one of the blockbusters among 
drugs in general. In addition to broad indications in on-
cology, it is applicable in ophthalmology, in age-related 
macular degeneration (AMD). Unlike the previously 
indicated examples, Avastin, according to the postulated 
mechanism of action, does not target growth factor re-
ceptors, but rather their ligands — specifically, vascular 
endothelial growth factor A (VEGF-A). It was marketed 
in 2004 as the first angiogenesis inhibitor. It was approved 
in the treatment of rectal and colorectal cancer, non-small 
cell lung cancer (NSCLC), kidney cancer, glioblastoma 
multiforme, and breast cancer. It was withdrawn from 
the last indication by the FDA in 2010 [20]. Another 
example of the molecule targeting the VEGF pathway 
is ramucirumab (Cyramza), a fully human anti-KDR 
(kinase insert domain receptor) antibody. This quite new 
angiogenesis inhibitor was approved for the treatment of 
some gastrointestinal cancers and NSCLC in 2014.
Significantly, two angiogenesis inhibitors applied in 
oncology have registered indications for treatment of 
age-related macular degeneration (wet AMD). Bevaci-
zumab and Ziv-Aflibercept (Zaltrap) are present on the 
market in this way. The second one on the ophthalmic 
drug market is known as Eylea. It is a fusion protein 
consisting of the IgG1 Fc domain combined with two 
soluble receptor fragments. It is a VEGF-Trap type 
construction, additionally capable of interacting with 
PGF (placental growth factor). In oncology, Zaltrap is 
applied to treat metastatic colorectal cancer [21].
Immune checkpoints
A completely new, ground-breaking, and currently 
intensively explored strategy in oncology is the applica-
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Figure 3. Biologics among the 10 drugs with the highest forecast sales value in 2019 (based on [25])
tion of immune checkpoint inhibitors for therapy. It is 
thanks to them that the neoplasm, in the development 
process, creates an immunosuppressive environment 
around itself in which the immune system becomes inac-
tive towards it. Therefore, blocking the checkpoints by 
turning off receptors or ligands that negatively regulate 
immune cell function should, by definition, make the 
neoplasm visible and vulnerable again [22].
Ipilimumab (Yervoy), which constitutes an antibody 
directed against CTLA-4 (CD152; cytotoxic T-lym-
phocyte-associated protein 4), a protein present on the 
surface of T-lymphocytes, which have been activated by 
contact with an antigen, is the first recombinant molecule 
approved in 2011, striking a completely new type of mo-
lecular target. Ipilimumab, by blocking CTLA-4, prevents 
the lymphocytes from transmitting a negative feedback 
signal by APC (antigen presenting cells), due to which 
neoplastic cells are not recognised as their own. Thus, 
lymphocyte deactivation does not occur. Ipilimumab is 
approved in the treatment of inoperable melanoma and 
kidney cancer [23].
PD-1 (programmed cell death protein 1) signal in-
hibitors function on the basis of a simpler mechanism. 
Nivolumab (Opdivo), pembrolizumab (Keytruda) and 
cemiplimab (Libtayo) are directed at the PD-1 receptor, 
present on the surface of the activated lymphocytes. This 
receptor is responsible for negative regulation of the im-
mune response. Inactivation of the receptor by antibod-
ies prevents recognition of the neoplastic cells as their 
own, by blocking the interaction with the PD-L1 ligand 
present on them [24]. By the time cemiplimab was ap-
proved in 2018, the other two molecules had already 
broadened their indications and were intensively con-
quering the market. As estimated by Evaluate, Keytruda, 
and Opdivo, sales are expected to reach 9.17 billion 
USD and 7.8 billion USD, respectively, in 2019 (Fig. 3).
The most intuitive approach in the group of check-
point inhibitors, based on targeting the neoplasm itself, 
and not directly the cells of the immune system of the 
patient, is represented by atezolizumab (Tecentriq), 
durvalumab (Imfinzi), and avelumab (Bavencio). These 
particles are targeted at PD-L1. They prevent its interac-
tion with PD-1 and CD80.
Thus, in just a few years, the market for immune 
checkpoint inhibitors filled with as many as seven mol-
ecules. Subsequent players are forced to make difficult 
business decisions related to the selection of indica-
tions. It should be noted that PD-1 and CTLA-4 are 
not the only molecular targets under this approach to 
treatment of neoplasms. May the next molecules based 
on LAG-3, TIM-3, B7-H3/4, and BTLA signalling con-
stitute another breakthrough.
Table 1 shows selected representatives of various 
classes of oncological biologics. Figure 4 presents on-
cological biologics with the highest sales value in 2017.
CAR-T and the future of oncological 
treatment
In 2017, the FDA issued a approval in B lympho-
blastic leukaemia derived from B lymphocytes for the 
first Novartis (Kymriah) therapy based on CAR-T 
technology. As part of the treatment, the patient’s 
T-lymphocytes are collected and genetically modi-
fied so that additional receptors (Chimeric antigen 
receptors) appear on their surface, in this particular 
case directed at CD19. Afterwards, the cells return 
to the patient. In the Evaluate’s 2018 report on the 
list of the most promising research programs, two 
further CAR-T projects in the Celgene pipeline in the 
third phase of clinical development are mentioned: 
bb2121 (anti-BCMA) and JCAR017 (anti-CD19). 
There are many more similar programs in preclinical 
development, and the interest in CAR technology is 
growing [25].
We are certainly at a very interesting point in the 
history of oncological biologics. The achievements of 
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Structure Molecular  
target
Company
1986 IFN alfa 2a Roferon A Rh-interferon alfa 2a IFN-alfa receptor Roche
1986 IFN alfa 2b Intron A Rh-interferon alfa 2b IFN-alfa receptor MSD
1992 Aldesleukin Proleukin rIL-2 IL-2 receptor Chiron/Novartis
1994 Filgrastim Neupogen rhG-CSF G-CSF receptor Roche
1997 Rituximab Rituxan mAb CD20 Roche
1998 Trastuzumab Herceptin mAb HER2 Roche
1998 Thyreotropin alfa Thyrogen rhTSH alfa TSH receptor Genzyme
1999 Denileukin diftitox Ontak rIL-2-diptheria toxin IL-2 receptor, EF-2 Eisai
2001 Alemtuzumab Campath mAb CD52 Bayer
2002 Peg-filgrastim Neulasta PEG-rhG-CSF G-CSF receptor Amgen
2004 Bevacizumab Avastin mAb VEGF-A Roche
2004 Cetuximab Erbitux mAb EGFR Merck
2006 Panitumumab Vectibix mAb EGFR Amgen
2009 Catumaxomab Removab mAb CD3, EpCAM Fresenius
2011 Ipilimumab Yervoy mAb CTLA-4 Bristol-Myers Squibb
2011 Brentuximab vedotin Adcetris ADC CD30 Seattle Genetics
2012 Ziv-aflibercept Zaltrap Fc(IgG1)-VEGF-Trap VEGF-A, VEGF-B, PGF Sanofi
2013 Pertuzumab Perjeta mAb HER2 Roche
2013 Trastuzumab emtansine Kadcyla ADC HER2 Roche
2014 Nivolumab Opdivo mAb PD-1 Bristol-Myers Squibb
2014 Pembrolizumab Keytruda mAb PD-1 MSD
2014 Ramucirumab Cyramza mAb VEGFR2 Lilly
2014 Blinatumomab Blincyto BiTE CD19, CD3 Amgen
2016 Atezolizumab Tecentriq mAb PD-L1 Roche
2017 Durvalumab Imfinzi mAb PD-L1 AstraZeneca
2017 Rituximab hyaluronidaze Rituxan Hycela mAb + rh– 
hyaluronidase
CD20 Biogen/Genentech
2017 Avelumab Bavencio mAb PD-L1 Pfizer/Merck


























Figure 4. Biologics in oncology with the highest sales value in 2017 (based on [26]) 
21
Bartłomiej Żerek et al., The evolution of biologics in the context of oncological therapy
scientist in recent years have given birth to new drug 
delivery technologies and have pointed to completely 
new, previously underestimated or unknown molecular 
targets. Improvement as part of the development of the 
so-called ‘biobetters’ will also apply to already tested 
drugs. From the point of view of the cost of therapy 
and availability for the patient, approvals of biosimilar 
drugs should be important. Unfortunately, in oncol-
ogy, only three molecules have appeared on the Euro-
pean market: trastuzumab (Ontruzant) from Samsung 
Bioepis, rituximab (Rixathon) from Sandoz, and rituxi-
mab (Truxima) from Celltrion. Thus, the market is still 
within a very narrow group of manufacturers who care 
about their interests.
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